Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

[Severe apathy following head injury: improvement with Selegiline treatment].

Moutaouakil F, El Otmani H, Fadel H, Slassi I.

Neurochirurgie. 2009 Dec;55(6):551-4. doi: 10.1016/j.neuchi.2008.10.009. Epub 2008 Dec 11. French.

PMID:
19084243
2.

Selegiline in the management of apathy following traumatic brain injury.

Newburn G, Newburn D.

Brain Inj. 2005 Feb;19(2):149-54.

PMID:
15841758
3.

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.

Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F.

Mov Disord. 1998 Jan;13(1):46-51.

PMID:
9452325
4.
5.

[Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].

Bettini R, Gorini M.

Clin Ter. 2002 Nov-Dec;153(6):377-80. Italian.

PMID:
12645393
6.

Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.

Caslake R, Macleod A, Ives N, Stowe R, Counsell C.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006661. doi: 10.1002/14651858.CD006661.pub2. Review.

PMID:
19821381
7.

Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.

Riederer P, Jellinger K, Danielczyk W, Seemann D, Ulm G, Reynolds GP, Birkmayer W, Koppel H.

Adv Neurol. 1983;37:159-76. No abstract available.

PMID:
6407285
8.

Selegiline transdermal system Somerset.

Mahmood I.

Curr Opin Investig Drugs. 2002 Aug;3(8):1230-3. Review.

PMID:
12211421
9.

A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.

Clarke A, Johnson ES, Mallard N, Corn TH, Johnston A, Boyce M, Warrington S, MacMahon DG.

J Neural Transm (Vienna). 2003 Nov;110(11):1257-71.

PMID:
14628190
10.

Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits.

Levy R, Dubois B.

Cereb Cortex. 2006 Jul;16(7):916-28. Epub 2005 Oct 5. Review.

PMID:
16207933
11.

Selegiline for Alzheimer's disease.

Birks J, Flicker L.

Cochrane Database Syst Rev. 2003;(1):CD000442. Review.

PMID:
12535396
12.

Monoamine oxidase inhibitors--is it time to up the TEMPO?

Rascol O.

Lancet Neurol. 2003 Mar;2(3):142-3. No abstract available.

PMID:
12849233
13.

Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.

Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P.

Brain. 2010 Apr;133(Pt 4):1111-27. doi: 10.1093/brain/awq032. Epub 2010 Mar 17.

PMID:
20237128
14.

Selegiline for Alzheimer's disease.

Birks J, Flicker L.

Cochrane Database Syst Rev. 2000;(2):CD000442. Review. Update in: Cochrane Database Syst Rev. 2003;(1):CD000442.

PMID:
10796544
15.

Neurobehavioral outcome of closed head injury: implications for clinical trials.

Levin HS.

J Neurotrauma. 1995 Aug;12(4):601-10. Review.

PMID:
8683611
16.

[Evolution of the concept of apathy: the need for a multifactorial approach in schizophrenia].

Del-Monte J, Capdevielle D, Gély-Nargeot MC, Yazbek H, Pupier F, Boulenger JP, Raffard S.

Encephale. 2013 May;39 Suppl 1:S57-63. doi: 10.1016/j.encep.2012.11.005. Epub 2013 Jan 23. Review. French.

PMID:
23351930
17.

On the functions of monoamine oxidase, the emotions, and adaptation to stress.

Richardson JS.

Int J Neurosci. 1993 May;70(1-2):75-84. Review.

PMID:
8083027
18.
20.

[The usefulness of dopaminergic drugs in traumatic brain injury].

Orient-López F, Terre- Boliart R, Bernabeu-Guitart M, Ramón-Rona S, Pérez-Miras A.

Rev Neurol. 2002 Aug 16-31;35(4):362-6. Review. Spanish.

Supplemental Content

Support Center